These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590 [TBL] [Abstract][Full Text] [Related]
6. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes. Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167 [TBL] [Abstract][Full Text] [Related]
8. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439 [TBL] [Abstract][Full Text] [Related]
9. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021 [TBL] [Abstract][Full Text] [Related]
10. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine. Muralidharan G; Cooper JK; Hawes EM; Korchinski ED; Midha KK Eur J Clin Pharmacol; 1996; 50(1-2):121-8. PubMed ID: 8739822 [TBL] [Abstract][Full Text] [Related]
11. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Daly AK; Armstrong M; Monkman SC; Idle ME; Idle JR Pharmacogenetics; 1991 Oct; 1(1):33-41. PubMed ID: 1688241 [TBL] [Abstract][Full Text] [Related]
12. Lack of congruence of S-carboxymethyl-L-cysteine sulphoxidation and debrisoquine 4-hydroxylation in a Caucasian population. Haley CS; Waring RH; Mitchell SC; Shah RR; Idle JR; Smith RL Xenobiotica; 1985 May; 15(5):445-50. PubMed ID: 4036168 [TBL] [Abstract][Full Text] [Related]
13. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease. Bordet R; Broly F; Destée A; Libersa C Adv Neurol; 1996; 69():97-100. PubMed ID: 8615190 [No Abstract] [Full Text] [Related]
14. The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers. Philip PA; James CA; Rogers HJ Eur J Clin Pharmacol; 1989; 36(3):319-21. PubMed ID: 2744073 [TBL] [Abstract][Full Text] [Related]
15. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine. Gross AS; Phillips AC; Rieutord A; Shenfield GM Br J Clin Pharmacol; 1996 Apr; 41(4):311-7. PubMed ID: 8730977 [TBL] [Abstract][Full Text] [Related]
16. Polymorphic ochratoxin A hydroxylation in rat strains phenotyped as poor and extensive metabolizers of debrisoquine. Castegnaro M; Bartsch H; Bereziat JC; Arvela P; Michelon J; Broussolle L Xenobiotica; 1989 Feb; 19(2):225-30. PubMed ID: 2786290 [TBL] [Abstract][Full Text] [Related]
17. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Llerena A; Edman G; Cobaleda J; Benítez J; Schalling D; Bertilsson L Acta Psychiatr Scand; 1993 Jan; 87(1):23-8. PubMed ID: 8424321 [TBL] [Abstract][Full Text] [Related]